Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NBI-1140675
- Development stage
- Unknown
- Lead developer
- Neurocrine Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NBI-1140675 is an orally administered, selective second-generation small molecule inhibitor of the vesicular monoamine transporter 2 (VMAT2). It is being developed by Neurocrine Biosciences for the potential treatment of certain neurological and neuropsychiatric conditions, including hyperkinetic movement disorders such as tardive dyskinesia. VMAT2 inhibitors work by modulating presynaptic dopamine storage and release, which has been clinically validated as an effective approach for treating movement disorders. NBI-1140675 aims to provide differentiated therapeutic benefits compared to first-generation VMAT2 inhibitors[1][2][3][4][7][8][9].
02
Targets
VMAT2 (Vesicular monoamine transporter 2)
Beyond the preview
Go deeper on NBI-1140675.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NBI-1140675.